Literature DB >> 1325736

Hepatocellular carcinoma: a multivariate analysis of prognostic features in patients treated with hepatic arterial embolization.

H Shijo1, M Okazaki, H Higashihara, F Koganemaru, M Okumura.   

Abstract

The prognosis after hepatic arterial chemoembolization was retrospectively analyzed in relation to therapeutic modalities, stage of tumor, and degree of liver cirrhosis in 150 patients with solitary tumors of hepatocellular carcinoma. The analyses of life-table methods revealed that adjunct hepatectomy, tumor size, bilirubin, albumin, globulin, and the 15-min retention rate of indocyanine green are statistically significant prognostic factors for hepatic arterial chemoembolization. Results of Cox's proportional hazard analyses disclosed that adjunct hepatectomy (p = 0.0001), serum albumin level (p = 0.0032), and stage of tumor (p = 0.0194) are statistically significant and independent prognostic factors. These findings suggest that the prognosis after hepatic arterial chemoembolization depends on the hepatic functional reserve and stage of tumor in patients with hepatocellular carcinoma, and adjunct hepatectomy improves the prognosis in these patients.

Entities:  

Mesh:

Year:  1992        PMID: 1325736

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

1.  Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma?

Authors:  T Harada; K Matsuo; T Inoue; S Tamesue; T Inoue; H Nakamura
Journal:  Ann Surg       Date:  1996-07       Impact factor: 12.969

2.  Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?

Authors:  Tsung-Hsing Hung; Chen-Chi Tsai; Chung-Chi Lin; Hsing-Feng Lee; Chi-Jen Chu; Han-Chieh Lin
Journal:  Hepatol Int       Date:  2012-07-27       Impact factor: 6.047

3.  Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors, and association with intrahepatic tumor recurrence.

Authors:  Teh-Ia Huo; Wing-Yu Lui; Jaw-Ching Wu; Yi-Hsiang Huang; Kuang-Liang King; Che-Chuan Loong; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  World J Surg       Date:  2004-02-17       Impact factor: 3.352

4.  Treatment of unresectable primary liver cancer: with reference to cytoreduction and sequential resection.

Authors:  Z Y Tang; Y Q Yu; X D Zhou; Z C Ma; B H Yang; Z Y Lin; J Z Lu; K D Liu; Z Fan; Z C Zeng
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.